CervoMed (NASDAQ: CRVO) has announced additional data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod’s potential as a treatment for dementia with Lewy bodies (DLB).
According to CervoMed, FDA feedback on its Phase 3 trial design is anticipated in the fourth quarter of 2025.
In a statement, John Alam, MD, CEO of CervoMed and co-principal investigator of the RewinD-LB trial, commented, “With October recognized as Lewy Body Dementia Awareness Month, we are especially proud to share these new data from our Phase 2b RewinD-LB trial. The significant improvements compared to placebo in change in CDR-SB observed in the within-subject comparison, along with correlated reductions in a key biomarker of neurodegeneration further strengthen our confidence in neflamapimod’s potential as a treatment for DLB. Together with other insights gained from Phase 2b, these results have enabled us to refine and optimize the design of our planned Phase 3 trial as we await FDA feedback later this quarter.”
